The estimated Net Worth of Shawn M. Bowman is at least $1.06 Million dollars as of 22 September 2022. Mr Bowman owns over 1,000 units of Sanara MedTech stock worth over $621,611 and over the last 5 years he sold SMTI stock worth over $115,430. In addition, he makes $326,430 as Co-COO & Pres of Wound Care at Sanara MedTech.
Mr has made over 4 trades of the Sanara MedTech stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,000 units of SMTI stock worth $27,890 on 22 September 2022.
The largest trade he's ever made was selling 1,000 units of Sanara MedTech stock on 22 September 2022 worth over $27,890. On average, Mr trades about 250 units every 22 days since 2020. As of 22 September 2022 he still owns at least 18,550 units of Sanara MedTech stock.
You can see the complete history of Mr Bowman stock trades at the bottom of the page.
Shawn M. Bowman is the Co-COO & Pres of Wound Care at Sanara MedTech.
As the Co-COO & Pres of Wound Care of Sanara MedTech, the total compensation of Mr Bowman at Sanara MedTech is $326,430. There are 1 executives at Sanara MedTech getting paid more, with Zachary B. Fleming having the highest compensation of $345,410.
Mr Bowman is 46, he's been the Co-COO & Pres of Wound Care of Sanara MedTech since . There are 7 older and no younger executives at Sanara MedTech. The oldest executive at Sanara MedTech Inc. is Cathy Bradshaw, 67, who is the Pres of Wound Care Innovations LLC.
Shawn's mailing address filed with the SEC is 1200 SUMMIT AVE, SUITE 414, FORT WORTH, TX, 76102.
Over the last 5 years, insiders at Sanara MedTech have traded over $134,660 worth of Sanara MedTech stock and bought 963,856 units worth $8,000,005 . The most active insiders traders include Ronald T Nixon, James W Stuckert, and Zachary B. Fleming. On average, Sanara MedTech executives and independent directors trade stock every 148 days with the average trade being worth of $6,486,564. The most recent stock trade was executed by Zachary B. Fleming on 26 October 2021, trading 1,000 units of SMTI stock currently worth $34,040.
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Sanara MedTech executives and other stock owners filed with the SEC include: